The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Cyclosporine before PCI in Patients with Acute Myocardial Infarction.
Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. ⋯ In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.).
-
Comment Letter
Trends in Mental Health Care among Children and Adolescents.
-
Editorial Comment
Targeting Myocardial Reperfusion Injury - The Search Continues.
-
Randomized Controlled Trial Multicenter Study
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.
Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia. ⋯ Sebelipase alfa therapy resulted in a reduction in multiple disease-related hepatic and lipid abnormalities in children and adults with lysosomal acid lipase deficiency. (Funded by Synageva BioPharma and others; ARISE ClinicalTrials.gov number, NCT01757184.).